An Open-Label Safety and Tolerability Phase 1b Trial of CAN04 A Fully Humanized Anti-IL1RAP Monoclonal Antibody in Combination with Pembrolizumab in Subjects with Solid Tumors Progressing on PD-1/PD-L1 Inhibitor-Containing Regimens
Enrolling By Invitation
99 years or below
All
Phase
1
1 Location
Brief description of study
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer, head and neck squamous cell carcinoma, urothelial cancer, or malignant melanoma.
The study aims to establish a recommended dose of CAN04 in combination with the standard dose of pembrolizumab. Both CAN04 and pembrolizumab will be administered intravenously.
Adults with locally advanced
(incurable) or metastatic NSCLC (adenocarcinoma, adenosquamous, or
squamous), HNSCC, urothelial cancer, or malignant melanoma who
experienced progression after at least 12 weeks on previous PD-1/PD-L1
inhibitor-containing regimens can be considered for participation.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Cancer,Solid Tumors
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 843823
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
